Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04251117 · ClinicalTrials.gov registry record · Phase 1

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC

A Phase 1 study of HCC, sponsored by Geneos Therapeutics.

Active
Registry status
Phase 1
Development phase
36
Enrollment target
3
Study locations

NCT04251117 is a Phase 1 study of HCC that is active but no longer recruiting, run by Geneos Therapeutics. The registered enrollment target is 36 participants, below the 199-participant average among 13 other HCC trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04251117, a Phase 1 study of HCC, is active but no longer recruiting, sponsored by Geneos Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
3
Study locations

Study Summary

This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.

Conditions Studied

HCC

Interventions

  • DRUG Pembrolizumab
  • BIOLOGICAL INO-9012
  • BIOLOGICAL GNOS-PV02
  • DEVICE CELLECTRA®2000 EP Device

Study Locations (3)

Maryland

  • Johns Hopkins Hospital - Baltimore

New York

  • Icahn School of Medicine at Mount Sinai - New York

Other

  • Auckland Clinical Studies - Auckland

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2020-03-01
Est. Completion 2028-11-29
Phase Phase 1

Sponsor

Geneos Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04251117

The ClinicalTrials.gov registry entry for NCT04251117 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 13 other HCC trials with a reported enrollment target (82% lower). The listed sponsor is Geneos Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HCC appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT04251117 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, New York, Other.

Frequently Asked Questions

What is clinical trial NCT04251117 about?

NCT04251117 is a clinical study titled "GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC". This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.

What is the current status of trial NCT04251117?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2020-03-01. Estimated completion is 2028-11-29.

What conditions does trial NCT04251117 study?

This clinical trial studies the following conditions: HCC.

What interventions are being tested in trial NCT04251117?

The interventions under investigation include: Pembrolizumab (DRUG), INO-9012 (BIOLOGICAL), GNOS-PV02 (BIOLOGICAL), CELLECTRA®2000 EP Device (DEVICE).

Who is sponsoring clinical trial NCT04251117?

This trial is sponsored by Geneos Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04251117 being conducted?

This trial has 3 study locations across Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HCC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HCC

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.